Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 4, 2025 • 1:00 PM ET

Date/Time Source News Release
01/02/2025 07:45 AM EST GlobeNewswire Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
12/26/2024 06:59 AM EST GlobeNewswire Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
12/24/2024 06:55 AM EST GlobeNewswire Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
12/16/2024 08:37 AM EST GlobeNewswire Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal(TM) Format
10/10/2024 08:07 AM EDT GlobeNewswire Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
09/16/2024 04:06 PM EDT GlobeNewswire Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
09/12/2024 08:20 AM EDT GlobeNewswire Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
09/06/2024 07:55 AM EDT GlobeNewswire SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
09/06/2024 07:55 AM EDT GlobeNewswire Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
08/29/2024 04:25 PM EDT GlobeNewswire Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
Page

Additional News

As of January 4, 2025 • 1:00 PM ET

Date/Time Source News Release
Page